World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
57
Citations
12541
World Ranking
3616
National Ranking
134

Overview

Thorbald van Hall is affiliated with Leiden University Medical Center in the Netherlands. Their research focuses primarily on medicine, immunology, and microbiology, with a particular emphasis on immunology and oncology as key subfields.

The main topics of van Hall's work include:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Monoclonal and Polyclonal Antibodies Research
  • Immune cells in cancer
  • Virus-based gene therapy research

Their recent publications demonstrate involvement in exploring immune checkpoints, tumor microenvironments, and immune activation in cancer. Notable papers include:

  • "The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes" (2020, Cancer Cell)
  • "The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment" (2020, Clinical Cancer Research)
  • "Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors" (2021, Cancers)
  • "Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model" (2022, Gut)
  • "Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy" (2024, Cancer Cell)

Van Hall has frequently published in journals such as:

  • Journal for ImmunoTherapy of Cancer
  • Cancer Immunology Research
  • Cancer Cell
  • Regular and Young Investigator Award Abstracts
  • Cancers

Collaborative research features several frequent coauthors, including:

  • Sjoerd H. van der Burg
  • Jim Middelburg
  • Marjolein Sluijter
  • Marit J van Elsas
  • Christianne Groeneveldt

Their work spans various aspects of immune cell behavior within the tumor setting, with a focus on checkpoint pathways, T cell immunity, and macrophage activation relevant to therapeutic interventions in cancer. The research also addresses challenges related to bispecific antibody therapies and immune system activation mechanisms.

Best Publications

  • Therapeutic cancer vaccines

    Cornelis J.M. Melief;Thorbald van Hall;Ramon Arens;Ferry Ossendorp

  • Vaccines for established cancer: overcoming the challenges posed by immune evasion.

    Sjoerd H. van der Burg;Ramon Arens;Ferry Ossendorp;Thorbald van Hall

  • The urgent need to recover MHC class I in cancers for effective immunotherapy

    Federico Garrido;Natalia Aptsiauri;Elien M Doorduijn;Angel M Garcia Lora

  • The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

    Floris Dammeijer;Mandy van Gulijk;Evalyn E. Mulder;Melanie Lukkes

  • Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.

    J. P. Medema;J. De Jong;T. Van Hall;C. J. M. Melief

  • M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.

    Moniek Heusinkveld;Peggy J. de Vos van Steenwijk;Renske Goedemans;Tamara H. Ramwadhdoebe

  • Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

    Marieke F. Fransen;Mark Schoonderwoerd;Philipp Knopf;Marcel G.M. Camps

  • NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

    Nadine van Montfoort;Linda Borst;Michael J. Korrer;Marjolein Sluijter

  • DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells

    Mattias Carlsten;Niklas K. Björkström;Håkan Norell;Yenan Bryceson

  • Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

    Michel P.M. Vierboom;Hans W. Nijman;Rienk Offringa;Ellen I.H. van der Voort

  • Monalizumab: inhibiting the novel immune checkpoint NKG2A

    Thorbald van Hall;Pascale André;Amir Horowitz;Dan Fu Ruan

  • Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

    Rodney A. Rosalia;Esther D. Quakkelaar;Anke Redeker;Selina Khan

  • HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes

    Marloes Jm Gooden;Margit H Lampen;Ekaterina S Jordanova;Ninke Leffers

  • Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.

    Selina Khan;Martijn S. Bijker;Jimmy J. Weterings;Hans J. Tanke

  • The NKG2A - HLA-E axis as a novel checkpoint in the tumor microenvironment

    Linda Borst;Sjoerd H van der Burg;Thorbald van Hall

  • Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

    Thorbald van Hall;Elisabeth Z Wolpert;Peter van Veelen;Sandra Laban

  • Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity

    Nadine van Montfoort;Marcel G. Camps;Selina Khan;Dmitri V. Filippov

  • PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.

    Jan Willem Kleinovink;Koen A. Marijt;Mark J. A. Schoonderwoerd;Thorbald van Hall

  • Dendritic Cells Break Tolerance and Induce Protective Immunity against a Melanocyte Differentiation Antigen in an Autologous Melanoma Model

    Marco W. J. Schreurs;Andreas A. O. Eggert;Annemiek J. de Boer;Joost L. M. Vissers

  • Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.

    Floris Dammeijer;Lysanne A. Lievense;Margaretha E H Kaijen-Lambers;Menno van Nimwegen

  • Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28

    Thorbald van Hall;Alice Sijts;Marcel Camps;Rienk Offringa

Frequent Co-Authors

Sjoerd H. van der Burg
Sjoerd H. van der Burg Leiden University Medical Center
Ferry Ossendorp
Ferry Ossendorp Leiden University Medical Center
Cornelis J. M. Melief
Cornelis J. M. Melief ISA Pharmaceuticals (Netherlands)
Rienk Offringa
Rienk Offringa German Cancer Research Center
Martine J. Jager
Martine J. Jager Leiden University Medical Center
Ramon Arens
Ramon Arens Leiden University Medical Center
Peter A. van Veelen
Peter A. van Veelen Leiden University Medical Center
Ekaterina S. Jordanova
Ekaterina S. Jordanova Vrije Universiteit Amsterdam
Jan W. Drijfhout
Jan W. Drijfhout Leiden University Medical Center
J. Sjef Verbeek
J. Sjef Verbeek Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various healthcare roles, many of which can be pursued through specialized online programs. For those interested in advancing their clinical expertise alongside immunological knowledge, an nurse practitioner accelerated program offers a fast-tracked route to becoming a licensed nurse practitioner.

Individuals without prior nursing experience can explore flexible options like online RN programs for non nurses in Florida, designed to smoothly transition students into registered nursing careers. These programs often integrate foundational science courses relevant to Immunology.

If accessibility is a priority, the easiest accelerated nursing programs provide manageable admission requirements and quicker completion timelines, ideal for students eager to enter the healthcare workforce promptly.

For entry-level nursing roles that complement immunological expertise, consider enrolling in accredited LPN programs easy to get into. These pathways offer foundational clinical skills and can serve as stepping stones to higher degrees in immunology-related fields.

Best Scientists Citing Thorbald van Hall

Trending Scientists

Recently Published Articles